	US 12,351,876 B2
	Colon cancer methylation markers and uses thereof
Kang Zhang, San Diego, CA (US); Rui Hou, Shenyang (CN); and Lianghong Zheng, Shenyang (CN)
Assigned to Helio Health, Inc., Irvine, CA (US); and The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/315,608
Filed by YouHealth Oncotech, Limited, Grand Cayman (KY); and The Regents of the University of California, Oakland, CA (US)
PCT Filed Jul. 6, 2017, PCT No. PCT/US2017/040945 § 371(c)(1), (2) Date Jan. 4, 2019, PCT Pub. No. WO2018/009696, PCT Pub. Date Jan. 11, 2018.
Claims priority of provisional application 62/358,776, filed on Jul. 6, 2016.
Prior Publication US 2019/0300964 A1, Oct. 3, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C07H 21/04 (2006.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/154 (2013.01)]

13 Claims

1. A method of treating a colon cancer in a subject, the method comprising:

(a) obtaining a treated genomic DNA sample derived from a cell-free DNA (cfDNA) sample from the subject, wherein the treated genomic DNA sample is suitable for a methylation analysis;

(b) performing a next-generation sequencing technique on the treated genomic DNA;

(c) mapping sequencing reads from the next-generation sequencing technique to a reference genome using a software tool to determine the methylation status of cg10673833 and cg08088171;

(d) generating a methylation profile comprising data of the methylation status cg10673833 and cg08088171;

(e) identifying the subject as having the colon cancer by comparing the methylation profile with a control; and

(f) administering to the subject having the colon cancer an effective amount of a therapeutic agent selected from the group consisting of capecitabine, cetuximab, doxorubicin, fluorouracil injection, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, panitumumab, ramucirumab, regorafenib, Ziv-aflibercept, and a combination thereof.